Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Connecting cancer relapse with senescence.

Pluquet O, Abbadie C, Coqueret O.

Cancer Lett. 2019 Oct 28;463:50-58. doi: 10.1016/j.canlet.2019.08.004. Epub 2019 Aug 9.

PMID:
31404612
2.

Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity.

Guillon J, Petit C, Toutain B, Guette C, Lelièvre E, Coqueret O.

Cell Cycle. 2019 Oct;18(19):2385-2397. doi: 10.1080/15384101.2019.1652047. Epub 2019 Aug 9.

PMID:
31397193
3.

OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.

Valo I, Raro P, Boissard A, Maarouf A, Jézéquel P, Verriele V, Campone M, Coqueret O, Guette C.

Proteomics. 2019 Nov;19(21-22):e1800446. doi: 10.1002/pmic.201800446. Epub 2019 Aug 8.

PMID:
31318138
4.

Proteomics Approaches to Define Senescence Heterogeneity and Chemotherapy Response.

Petit C, Guillon J, Toutain B, Boissard A, Patsouris A, Lelièvre E, Guette C, Coqueret O.

Proteomics. 2019 Nov;19(21-22):e1800447. doi: 10.1002/pmic.201800447. Epub 2019 May 13.

PMID:
30968557
5.

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment.

Guillon J, Petit C, Moreau M, Toutain B, Henry C, Roché H, Bonichon-Lamichhane N, Salmon JP, Lemonnier J, Campone M, Verrièle V, Lelièvre E, Guette C, Coqueret O.

Cell Death Dis. 2019 Feb 27;10(3):199. doi: 10.1038/s41419-019-1406-7.

6.

Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma.

Nader JS, Abadie J, Deshayes S, Boissard A, Blandin S, Blanquart C, Boisgerault N, Coqueret O, Guette C, Grégoire M, Pouliquen DL.

Oncotarget. 2018 Mar 27;9(23):16311-16329. doi: 10.18632/oncotarget.24632. eCollection 2018 Mar 27.

7.

Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy.

Le Duff M, Gouju J, Jonchère B, Guillon J, Toutain B, Boissard A, Henry C, Guette C, Lelièvre E, Coqueret O.

Cell Death Dis. 2018 Feb 7;9(2):199. doi: 10.1038/s41419-017-0209-y.

8.

BCL-XL directly modulates RAS signalling to favour cancer cell stemness.

Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP.

Nat Commun. 2017 Oct 24;8(1):1123. doi: 10.1038/s41467-017-01079-1.

9.

Senescence: Adaptation to DNA repair targeting drugs?

Coqueret O.

Cell Cycle. 2016 Oct;15(19):2549-2550. Epub 2016 Aug 2. No abstract available.

10.

[Contribution to tumor escape and chemotherapy response: A choice between senescence and apoptosis in heterogeneous tumors].

Jonchère B, Vétillard A, Toutain B, Guette C, Coqueret O.

Bull Cancer. 2016 Jan;103(1):73-86. doi: 10.1016/j.bulcan.2015.10.014. Epub 2016 Jan 4. Review. French.

PMID:
26762946
11.

Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis.

Vétillard A, Jonchère B, Moreau M, Toutain B, Henry C, Fontanel S, Bernard AC, Campone M, Guette C, Coqueret O.

Oncotarget. 2015 Dec 22;6(41):43342-62. doi: 10.18632/oncotarget.6126.

12.

Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples.

Campone M, Valo I, Jézéquel P, Moreau M, Boissard A, Campion L, Loussouarn D, Verriele V, Coqueret O, Guette C.

Mol Cell Proteomics. 2015 Nov;14(11):2936-46. doi: 10.1074/mcp.M115.048967. Epub 2015 Jul 24.

13.

Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1.

Jonchère B, Vétillard A, Toutain B, Lam D, Bernard AC, Henry C, De Carné Trécesson S, Gamelin E, Juin P, Guette C, Coqueret O.

Oncotarget. 2015 Jan 1;6(1):409-26.

14.

Imidacloprid and thiacloprid neonicotinoids bind more favourably to cockroach than to honeybee α6 nicotinic acetylcholine receptor: insights from computational studies.

Selvam B, Graton J, Laurent AD, Alamiddine Z, Mathé-Allainmat M, Lebreton J, Coqueret O, Olivier C, Thany SH, Le Questel JY.

J Mol Graph Model. 2015 Feb;55:1-12. doi: 10.1016/j.jmgm.2014.10.018. Epub 2014 Nov 8.

PMID:
25424654
15.

Olfactomedin-4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers.

Guette C, Valo I, Vétillard A, Coqueret O.

Proteomics Clin Appl. 2015 Feb;9(1-2):58-63. doi: 10.1002/prca.201400083. Epub 2014 Dec 28. Review.

PMID:
25400027
16.

Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties.

Clavreul A, Guette C, Faguer R, Tétaud C, Boissard A, Lemaire L, Rousseau A, Avril T, Henry C, Coqueret O, Menei P.

J Pathol. 2014 May;233(1):74-88. doi: 10.1002/path.4332. Epub 2014 Feb 20.

PMID:
24481573
17.

Two-step OFFGEL approach for effective peptide separation compatible with iTRAQ labeling.

Rideau A, Besson D, Boissard A, Coqueret O, Guette C.

Proteomics. 2013 Nov;13(22):3261-6. doi: 10.1002/pmic.201300161. Epub 2013 Oct 20.

PMID:
24115339
18.

How should we define STAT3 as an oncogene and as a potential target for therapy?

Sellier H, Rébillard A, Guette C, Barré B, Coqueret O.

JAKSTAT. 2013 Jul 1;2(3):e24716. doi: 10.4161/jkst.24716. Epub 2013 Apr 16. Review.

19.

STAT3 as a new autophagy regulator.

Jonchère B, Bélanger A, Guette C, Barré B, Coqueret O.

JAKSTAT. 2013 Jul 1;2(3):e24353. doi: 10.4161/jkst.24353. Epub 2013 Aug 15.

20.

Circulating miRNAs as new activators of the JAK-STAT3 pathway.

Lam D, Barré B, Guette C, Coqueret O.

JAKSTAT. 2013 Jan 1;2(1):e22996. doi: 10.4161/jkst.22996.

21.

Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells.

Weber A, Borghouts C, Delis N, Mack L, Brill B, Bernard AC, Coqueret O, Groner B.

Horm Mol Biol Clin Investig. 2012 Jun;10(2):273-9. doi: 10.1515/hmbci-2012-0014.

PMID:
25436684
22.

A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.

Besson D, Pavageau AH, Valo I, Bourreau A, Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A, Boisdron-Celle M, Morel A, Solassol J, Campone M, Gamelin E, Barré B, Coqueret O, Guette C.

Mol Cell Proteomics. 2011 Dec;10(12):M111.009712. doi: 10.1074/mcp.M111.009712. Epub 2011 Oct 10.

23.

c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.

Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S, Juin P.

Mol Cancer. 2011 Sep 7;10:110. doi: 10.1186/1476-4598-10-110.

24.

Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.

Basseville A, Preisser L, de Carné Trécesson S, Boisdron-Celle M, Gamelin E, Coqueret O, Morel A.

Mol Cancer. 2011 Jul 6;10:80. doi: 10.1186/1476-4598-10-80.

25.

Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins.

de Carné Trécesson S, Guillemin Y, Bélanger A, Bernard AC, Preisser L, Ravon E, Gamelin E, Juin P, Barré B, Coqueret O.

J Biol Chem. 2011 Apr 15;286(15):12825-38. doi: 10.1074/jbc.M110.186437. Epub 2011 Feb 3.

26.

Regulation of activity and function of the p52 NF-κB subunit following DNA damage.

Barré B, Coqueret O, Perkins ND.

Cell Cycle. 2010 Dec 15;9(24):4795-804. Epub 2010 Dec 15. Retraction in: Cell Cycle. 2014;13(14):2312.

PMID:
21131783
27.

Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factor.

Courapied S, Cherier J, Vigneron A, Troadec MB, Giraud S, Valo I, Prigent C, Gamelin E, Coqueret O, Barré B.

Mol Cancer. 2010 Aug 3;9:205. doi: 10.1186/1476-4598-9-205.

28.

The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition.

Courapied S, Sellier H, de Carné Trécesson S, Vigneron A, Bernard AC, Gamelin E, Barré B, Coqueret O.

J Biol Chem. 2010 Aug 27;285(35):26765-78. doi: 10.1074/jbc.M109.092304. Epub 2010 Jun 1.

29.

[Transient transformation as a permanent oncogenic loop].

Coqueret O, Barré B.

Med Sci (Paris). 2010 Apr;26(4):339-41. doi: 10.1051/medsci/2010264339. French. No abstract available.

30.

Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis.

Clere N, Corre I, Faure S, Guihot AL, Vessières E, Chalopin M, Morel A, Coqueret O, Hein L, Delneste Y, Paris F, Henrion D.

Int J Cancer. 2010 Nov 15;127(10):2279-91. doi: 10.1002/ijc.25234.

31.

The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition.

Vigneron A, Gamelin E, Coqueret O.

Cancer Res. 2008 Feb 1;68(3):815-25. doi: 10.1158/0008-5472.CAN-07-5115.

32.

Cell cycle and cell death associates in western France.

Coqueret O, Barillé-Nion S, Juin P.

Cell Death Differ. 2007 May;14(5):1066-7. Epub 2007 Feb 2. No abstract available.

33.

The STAT3 oncogene as a predictive marker of drug resistance.

Barré B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O.

Trends Mol Med. 2007 Jan;13(1):4-11. Epub 2006 Nov 21.

PMID:
17118707
34.

The cell cycle inhibitor p21waf1 binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression.

Vigneron A, Cherier J, Barré B, Gamelin E, Coqueret O.

J Biol Chem. 2006 Nov 17;281(46):34742-50. Epub 2006 Aug 21.

35.

Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1.

Vigneron A, Roninson IB, Gamelin E, Coqueret O.

Cancer Res. 2005 Oct 1;65(19):8927-35.

36.

The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the Cdc25A promoter.

Barré B, Vigneron A, Coqueret O.

J Biol Chem. 2005 Apr 22;280(16):15673-81. Epub 2005 Jan 26.

37.

Transcriptional regulation by a DNA-associated form of cyclin D1.

Bienvenu F, Barré B, Giraud S, Avril S, Coqueret O.

Mol Biol Cell. 2005 Apr;16(4):1850-8. Epub 2005 Jan 19.

39.

Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene.

Giraud S, Hurlstone A, Avril S, Coqueret O.

Oncogene. 2004 Sep 23;23(44):7391-8.

PMID:
15286705
40.

New targets for viral cyclins.

Coqueret O.

Cell Cycle. 2003 Jul-Aug;2(4):293-5. Review.

PMID:
12851476
41.

New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?

Coqueret O.

Trends Cell Biol. 2003 Feb;13(2):65-70. Review.

PMID:
12559756
42.

Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition.

Lundquist A, Barré B, Bienvenu F, Hermann J, Avril S, Coqueret O.

Blood. 2003 May 15;101(10):4070-7. Epub 2003 Jan 16.

PMID:
12531804
43.

Linking cyclins to transcriptional control.

Coqueret O.

Gene. 2002 Oct 16;299(1-2):35-55. Review.

PMID:
12459251
44.

Opposite regulation of myc and p21waf1 transcription by STAT3 proteins.

Barré B, Avril S, Coqueret O.

J Biol Chem. 2003 Jan 31;278(5):2990-6. Epub 2002 Nov 15. Retraction in: J Biol Chem. 2014 Jun 13;289(24):16643.

45.

Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a.

Giraud S, Bienvenu F, Avril S, Gascan H, Heery DM, Coqueret O.

J Biol Chem. 2002 Mar 8;277(10):8004-11. Epub 2001 Dec 31.

46.

Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism.

Bienvenu F, Gascan H, Coqueret O.

J Biol Chem. 2001 May 18;276(20):16840-7. Epub 2001 Feb 20.

47.
49.

DNA binding by cut homeodomain proteins is down-modulated by casein kinase II.

Coqueret O, Martin N, Bérubé G, Rabbat M, Litchfield DW, Nepveu A.

J Biol Chem. 1998 Jan 30;273(5):2561-6.

50.

Supplemental Content

Loading ...
Support Center